Clene (NASDAQ:CLNN) Major Shareholder Sells $36,815.28 in Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 5,816 shares of the stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $6.33, for a total transaction of $36,815.28. Following the completion of the sale, the insider directly owned 393,150 shares in the company, valued at $2,488,639.50. This trade represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The shares were sold at an average price of $7.86, for a total value of $444,695.22.
• On Wednesday, December 17th, Chidozie Ugwumba sold 2,884 shares of Clene stock. The shares were sold at an average price of $6.61, for a total value of $19,063.24.
• On Tuesday, December 16th, Chidozie Ugwumba sold 7,030 shares of Clene stock. The stock was sold at an average price of $6.31, for a total value of $44,359.30.
• On Monday, December 15th, Chidozie Ugwumba sold 10,580 shares of Clene stock. The stock was sold at an average price of $6.49, for a total value of $68,664.20.
• On Friday, December 12th, Chidozie Ugwumba sold 7,603 shares of Clene stock. The shares were sold at an average price of $6.79, for a total value of $51,624.37.
• On Thursday, December 11th, Chidozie Ugwumba sold 10,907 shares of Clene stock. The stock was sold at an average price of $6.81, for a total value of $74,276.67.
• On Wednesday, December 10th, Chidozie Ugwumba sold 9,921 shares of Clene stock. The stock was sold at an average price of $6.42, for a total value of $63,692.82.
• On Tuesday, December 9th, Chidozie Ugwumba sold 15,031 shares of Clene stock. The shares were sold at an average price of $5.95, for a total transaction of $89,434.45.
• On Monday, December 8th, Chidozie Ugwumba sold 21,463 shares of Clene stock. The stock was sold at an average price of $5.70, for a total transaction of $122,339.10.
• On Friday, December 5th, Chidozie Ugwumba sold 37,235 shares of Clene stock. The stock was sold at an average price of $5.94, for a total transaction of $221,175.90.

Clene Price Performance

Shares of CLNN opened at $6.68 on Friday. The firm has a market capitalization of $69.00 million, a price-to-earnings ratio of -1.97 and a beta of 0.79. Clene Inc. has a 1-year low of $2.28 and a 1-year high of $13.50. The company has a 50-day moving average of $8.51 and a 200 day moving average of $6.23.

Clene (NASDAQ:CLNN) last issued its earnings results on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. On average, equities analysts anticipate that Clene Inc. will post -5.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp purchased a new stake in shares of Clene during the 3rd quarter worth $29,000. Jane Street Group LLC purchased a new position in Clene in the second quarter valued at about $47,000. Lunt Capital Management Inc. raised its holdings in Clene by 71.2% in the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after purchasing an additional 21,217 shares in the last quarter. Finally, Scoggin Management LP lifted its position in shares of Clene by 42.8% during the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after buying an additional 42,750 shares during the last quarter. 23.28% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CLNN. UBS Group reiterated a “buy” rating on shares of Clene in a report on Wednesday, December 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a report on Tuesday, October 14th. D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Clene in a research note on Wednesday, December 10th. Finally, Benchmark reissued a “buy” rating on shares of Clene in a research report on Thursday, December 4th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Clene has an average rating of “Moderate Buy” and a consensus target price of $32.60.

Clene News Summary

Here are the key news stories impacting Clene this week:

• Positive Sentiment: Sell‑side support remains — several research firms (Benchmark, UBS, D. Boral Capital) continue to carry Buy ratings and elevated targets, which can limit downside and support rebounds. MarketBeat CLNN
• Neutral Sentiment: Institutional activity mixed — some hedge funds increased or initiated positions (e.g., Scoggin Management added shares), meaning a portion of supply is being absorbed by institutions rather than retail. MarketBeat Holdings
• Negative Sentiment: Material insider selling by a major shareholder — Ugwumba disclosed many transactions from Dec. 3–17 totaling roughly ~258k shares sold across multiple days (including a 72,748 share sale on Dec. 4 that was reported as a 12.24% position reduction). Heavy, concentrated selling from a >10% holder puts clear downward pressure and likely explains the intraday weakness. InsiderTrades Article
• Negative Sentiment: Weak recent operating results — the company missed Q3 revenue and EPS expectations (reported -$0.85 vs. consensus -$0.60; revenue essentially immaterial), keeping the story speculative and increasing sensitivity to insider flows. SEC Filing

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).